News
-
-
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
Thalassaemia in the Americas | New TIF White Paper Calls for Coordinated Action and Equity in Care
Developed in the context of the 1st TIF Pan-American Conference on Thalassaemia and Other Haemoglobin Disorders, held in Washington, D.C. in July 2025, this publication provides the first region-wide, evidence-based…
Read More » -
The MENA Thalassaemia Experience: A Two-Day, In-Person Masterclass | Dubai, 24–25 April 2026
This high-level educational initiative is designed to strengthen clinical expertise, foster regional collaboration, and promote best practices in the management of thalassaemia across the Middle East and North Africa (MENA)…
Read More » -
U.S. Exit from WHO | Implications for Global Health Cooperation and Preparedness
The U.S. government said the decision was based on concerns about how the WHO handled previous global health emergencies, particularly the COVID-19 pandemic. According to U.S. officials, the organization did…
Read More » -
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug…
Read More » -
FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia
This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only therapy approved in the United States indicated for treating anaemia…
Read More » -
PUTTING PATIENTS FIRST IN CLINICAL RESEARCH | New EU Recommendations to Reduce Trials Bureaucracy
As Prof. Martin Dreyling, Chair of the Coalition for Reducing Bureaucracy, explains: “The current safety requirements for investigators are disproportionately burdensome, to the point that they may obscure relevant safety…
Read More » -
EU AGREES LANDMARK REFORM OF PHARMACEUTICAL LEGISLATION | What It Means for Patients and Public Health
This milestone agreement — part of what has been referred to as the “pharma package” — was negotiated between the European Commission, the European Parliament, and the Council of the…
Read More » -
